We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (DASISION)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00481247
First Posted: June 1, 2007
Last Update Posted: February 15, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Bristol-Myers Squibb
  Purpose
The purpose of this clinical research study is to compare the confirmed complete cytogenetic response of dasatinib with that of imatinib within 12 months after randomization in patients with newly diagnosed chronic-phase Philadelphia positive chronic myeloid leukemia. The safety of this treatment will also be studied.

Condition Intervention Phase
Myeloid Leukemia, Chronic Drug: Dasatinib Drug: Imatinib Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Randomized, Multicenter Phase III Trial of Dasatinib (SPRYCEL®) vs. Standard Dose Imatinib (400 mg) in the Treatment of Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia

Resource links provided by NLM:


Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:
  • Number of Participants With Best Confirmed Complete Cytogenetic Response (cCCyR) Within 12 Months [ Time Frame: Pretreatment, every 3 months up to 12 months ]
    Cytogenetic response (CyR) is based on the prevalence of Philadelphia positive (Ph+) cells in metaphase from bone marrow (BM) sample. (Ideally, 25 metaphases but at least 20 metaphases from a BM sample were evaluated). Complete Cytogenetic Response (CCyR)=0% Ph+ cells in metaphase in BM. A cCCyR=those in which all measurements up to at least 28 days after the initial response show an equivalent or better CCyR.


Secondary Outcome Measures:
  • Percentage of Participants Remaining in Confirmed Complete Cytogenetic Response (cCCyR) [ Time Frame: Years 2, 3, 4 and 5 ]

    Cytogenetic response (CyR) is based on the prevalence of Philadelphia positive (Ph+) cells in metaphase from bone marrow (BM) sample. (Ideally, 25 metaphases but at least 20 metaphases from a BM sample were evaluated). Complete Cytogenetic Response (CCyR)=0% Ph+ cells in metaphase in BM. A cCCyR=those in which all measurements up to at least 28 days after the initial response show an equivalent or better CCyR.

    Percentage of participants in cCCyR at years 2, 3, 4 and 5 was computed for all randomized participants who achieved cCCyR as measured from the time of first confirmation until the date of progression or death. Participants with cCCyR who neither progress nor die are censored on the date of their last cytogenetic assessment. Participants without cCCyR are considered to have progressed on Day 1.


  • Percentage of Participants With Major Molecular Response (MMR) at Any Time [ Time Frame: Planned total follow-up duration of 5 years ]
    Molecular response was assessed using BCR-ABL transcript levels measured by realtime quantitative polymerase chain reaction. MMR is defined as a ratio BCR-ABL/ABL ≤0.1% on the international scale (ie, at least 3 log reduction from a standardized baseline value).

  • Time to Confirmed Complete Cytogenic Response (cCCyR) Overall [ Time Frame: Day 1 to 5 years ]

    The time to cCCyR for all randomized participants is defined as the time from the randomization date until criteria are first met for complete cytogenic response (provided it is confirmed later). The time to cCCyR analysis censors nonresponders who do not progress at their last cytogenetic assessments and nonresponders who progress at the maximum time of all randomized participants.


  • Time to Major Molecular Response (MMR) Overall [ Time Frame: Day 1 to 5 years ]
    The time to MMR for all randomized participants is defined as the time from randomization date until measurement criteria are first met for MMR. The time to MMR analysis censors nonresponders who do not progress at their last molecular assessments and nonresponders who progress at the maximum time of all randomized participants.

  • Percentage of Participants With Progression-free Survival (PFS) [ Time Frame: Participants were followed-up for at least 5 years ]
    PFS was defined as the time from randomization until progression (any progression/death within 30 days of last dosing date, or between 30-60 days of last dosing prior to start of secondary therapy). Those who did not progress/die or who progressed/died after 60 days of last dose were censored at last on-study hematologic/cytogenetic assessment; those with progression/death 30-60 days of last dosing date and after start date of secondary therapy censored at last on-study hematologic/cytogenetic assessment prior to start of secondary therapy; those who had not received study treatment censored on date randomized.

  • Percentage of Participants With Overall Survival (OS) [ Time Frame: Participants were followed-up for at least 5 years ]
    OS was defined as the time from randomization to the date of death. If the participant had not died, survival was censored on last date the participant was known to be alive.


Other Outcome Measures:
  • Number of Participants With Adverse Events (AEs), Drug-related AEs, Drug-related Serious Adverse Events (SAEs), Drug-related AEs Leading to Discontinuation, and All Deaths [ Time Frame: From date of last person, first visit to date of last person, last visit (approximately 8 years) ]
    AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.

  • Number of Participants With Grade 3/4 Abnormalities in On-study Laboratory Test Results [ Time Frame: From date of last person, first visit to date of last person, last visit (approximately 8 years) ]
    ULN=upper limit of normal. Grade 3=Severe AE; Grade 4=Life-threatening or disabling AE. Absolute neutrophil count: Grade 3 <1000-500/mm^3; Grade 4 <500/mm^3. Hemoglobin: Grade 3 <8.0-6.5 g/dL; Grade 4 <6.5 g/dL. Platelets: Grade 3 <50,000-25,000/mm^3; Grade 4 <25,000/mm^3. ALT/AST: Grade 3 >5.0-20*ULN; Grade 4 >20*ULN. Total bilirubin: Grade 3 >3-10*ULN; Grade 4 >10*ULN. Sample normal ranges (may vary by institution): ALT, Female: 7-30 U/L, Male: 10-55 U/L; AST, Female: 9-25 U/L, Male10-40 U/L; Total bilirubin: 0.0-1.0 mg/dL. Creatinine: Grade 3 >3.0-6.0*ULN; Grade 4 >6.0*ULN. Phosphate: Grade 3 <2.0-1.0 mg/dL; Grade 4 <1.0 mg/dL. Calcium: Grade 3 <7.0-6.0 mg/dL; Grade 4 <6.0 mg/dL. Potassium: Grade 3 <3.0-2.5 mmol/L; Grade 4 <2.5 mmol/L.


Enrollment: 547
Study Start Date: September 2007
Study Completion Date: December 2015
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Dasatinib Drug: Dasatinib
Tablets, oral, dasatinib 50-140 mg once daily (QD)
Other Names:
  • Sprycel®
  • BMS-354825
Active Comparator: Imatinib Drug: Imatinib
Tablets, oral, imatinib 200-800 mg, QD

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Male or female, aged 18 years and older
  • Chronic phase, Philadelphia Chromosome-positive chronic myeloid leukemia (CML)
  • Eastern Cooperative Oncology Group Performance Status score of 0-2

Key Exclusion Criteria:

  • Pleural Effusion
  • Uncontrolled cardiovascular disease
  • Significant bleeding disorder unrelated to CML
  • Prior treatment with interferon/imatinib/dasatinib/anti-CML systemic treatments except anagrelide/hydroxyurea
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00481247


  Hide Study Locations
Locations
United States, Oregon
Molecular Md
Portland, Oregon, United States, 97219
Argentina
Local Institution
Capital Federal, Buenos Aires, Argentina, 1280
Local Institution
Capital Federal, Buenos Aires, Argentina, C1114AAN
Local Institution
Buenos Aires, Argentina, 1021
Australia, New South Wales
Local Institution
Waratah, New South Wales, Australia, 2298
Australia, Queensland
Local Institution
Brisbane, Queensland, Australia, 4029
Local Institution
Greenslopes, Queensland, Australia, 4120
Australia, Western Australia
Local Institution
Perth, Western Australia, Australia, WA 6000
Austria
Local Institution
Innsbruck, Austria, 6020
Local Institution
Wien, Austria, 1090
Belgium
Local Institution
Brugge, Belgium, 8000
Local Institution
Bruxelles, Belgium, 1200
Brazil
Local Institution
Curitiba, Parana, Brazil, 80060
Local Institution
Campinas, Sao Paulo, Brazil, 13083
Local Institution
Jau, Sao Paulo, Brazil, 17210
Local Institution
Rio De Janeiro, Brazil, 20230130
Local Institution
Sao Paulo, Brazil, 01401
Local Institution
Sao Paulo, Brazil, 05403
Chile
Local Institution
Santiago, Metropolitana, Chile
China, Beijing
Local Institution
Beijing, Beijing, China, 100044
China, Fujian
Local Institution
Fuzhou, Fujian, China, 350001
China, Shanghai
Local Institution
Shanghai, Shanghai, China, 200025
China, Tianjin
Local Institution
Tianjin, Tianjin, China, 300020
Colombia
Local Institution
Colombia, Bogota, Colombia
Local Institution
Bogota, Colombia
Czech Republic
Local Institution
Brno, Czech Republic, 625 00
Local Institution
Hradec Kralove, Czech Republic, 500 05
Local Institution
Olomouc, Czech Republic, 775 20
Local Institution
Prague 2, Czech Republic, 128 20
Denmark
Local Institution
Aarhus, Denmark, 8000
France
Local Institution
Nantes, Cedex 1, France, 44093
Local Institution
Brest Cedex 02, France, 29609
Local Institution
Lille Cedex, France, 59037
Local Institution
Limoges, France, 87042
Local Institution
Montpellier Cedex, France, 34295
Local Institution
Paris Cedex 10, France, 75475
Local Institution
Paris, France, 75015
Local Institution
Pierre Benite Cedex, France, 69495
Local Institution
Poitiers Cedex, France, 86021
Local Institution
Rennes, France, 35033
Local Institution
Strasbourg Cedex, France, 67091
Local Institution
Toulouse Cedex 09, France, 31059
Local Institution
Vandoeuvre Les Nancy, France, 54511
Germany
Local Institution
Berlin, Germany, 13353
Local Institution
Rostock, Germany, 18055
Local Institution
Tuebingen, Germany, 72076
Local Institution
Ulm, Germany, 89081
Greece
Local Institution
Thessaloniki, Greece, 57010
Hungary
Local Institution
Budapest, Hungary, 1097
Local Institution
Debrecen, Hungary, 4012
India
Local Institution
Vellore, Tamilnadu, India, 632004
Local Institution
Ahmedabad, India, 380009
Local Institution
Cochin, India, 682304
Local Institution
Mumbai, India, 400010
Local Institution
Mumbai, India, 400012
Local Institution
Mumbai, India, 400014
Local Institution
Trivandrum, India, 695011
Italy
Local Institution
Bologna, Italy, 40138
Local Institution
Catania, Italy, 95124
Local Institution
Monza (mb), Italy, 20900
Local Institution
Orbassano (to), Italy, 10043
Local Institution
Pavia, Italy, 27100
Local Institution
Roma, Italy, 00144
Local Institution
Roma, Italy, 00161
Japan
Local Institution
Nagoya, Aichi, Japan, 466-8650
Local Institution
Kamogawa-shi, Chiba, Japan, 2968602
Local Institution
Fukuoka-shi, Fukuoka, Japan, 814-0180
Local Institution
Morioka-shi, Iwate, Japan, 020-8505
Local Institution
Kagoshima-shi, Kagoshima, Japan, 890-0064
Local Institution
Yokohama, Kanagawa, Japan, 232-0024
Local Institution
Kyoto-shi, Kyoto, Japan, 6028566
Local Institution
Sendai, Miyagi, Japan
Local Institution
Okayama-shi, Okayama, Japan, 7008558
Local Institution
Osaka-shi, Osaka, Japan, 545-8586
Local Institution
Bunkyo-ku, Tokyo, Japan, 113-8677
Local Institution
Shinagawa-ku, Tokyo, Japan, 1418625
Korea, Republic of
Local Institution
Seoul, Korea, Republic of, 137-040
Local Institution
Seoul, Korea, Republic of, 138-736
Mexico
Local Institution
Mexico D.f., Distrito Federal, Mexico, 14000
Local Institution
Mexico, D. F., Distrito Federal, Mexico, 06726
Local Institution
Mexico, Distrito Federal, Mexico, 02990
Local Institution
Monterrey, Nuevo Leon, Mexico, 64460
Local Institution
Culiacan, Sinaloa, Mexico, 80230
Netherlands
Local Institution
Groningen, Netherlands, 9700 RB
Local Institution
Nijmegen, Netherlands, 6500 HB
Peru
Local Institution
Arequipa, Peru
Local Institution
Lima, Peru, 11
Local Institution
Lima, Peru, 34
Poland
Local Institution
Chorzow, Poland, 41-500
Local Institution
Krakow, Poland, 31501
Local Institution
Lodz, Poland, 93-510
Local Institution
Poznan, Poland, 60869
Local Institution
Warsaw, Poland, 02776
Russian Federation
Local Institution
Moscow, Russian Federation, 125167
Local Institution
Rostov-on-don, Russian Federation, 344022
Local Institution
St.petersburg, Russian Federation, 197022
Singapore
Local Institution
Singapore, Singapore, 169865
Spain
Local Institution
A Coruna, Spain, 15706
Local Institution
Barcelona, Spain, 08003
Local Institution
Barcelona, Spain, 08036
Local Institution
Barcelona, Spain, 08907
Local Institution
Madrid, Spain, 28006
Local Institution
Madrid, Spain, 28046
Local Institution
Malaga, Spain, 29010
Local Institution
Oviedo, Spain, 33006
Local Institution
Salamanca, Spain, 37007
Local Institution
Valencia, Spain, 46009
Turkey
Local Institution
Ankara, Turkey, 06100
Local Institution
Kayseri, Turkey, 38039
Sponsors and Collaborators
Bristol-Myers Squibb
Investigators
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
  More Information

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT00481247     History of Changes
Other Study ID Numbers: CA180-056
2006-005712-27 ( EudraCT Number )
First Submitted: May 30, 2007
First Posted: June 1, 2007
Results First Submitted: November 23, 2010
Results First Posted: March 15, 2011
Last Update Posted: February 15, 2017
Last Verified: December 2016

Keywords provided by Bristol-Myers Squibb:
Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia

Additional relevant MeSH terms:
Leukemia
Leukemia, Myeloid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Philadelphia Chromosome
Leukemia, Myeloid, Chronic-Phase
Neoplasms by Histologic Type
Neoplasms
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases
Translocation, Genetic
Chromosome Aberrations
Pathologic Processes
Imatinib Mesylate
Dasatinib
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action